Kevin Joseph Fitzgerald Sells 2,441 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 2,441 shares of the stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the transaction, the executive vice president owned 25,231 shares of the company’s stock, valued at approximately $11,405,673.55. The trade was a 8.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, August 18th, Kevin Joseph Fitzgerald sold 1,396 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total transaction of $632,764.92.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $456.35 on Friday. The firm has a market cap of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The firm has a 50-day moving average of $441.57 and a 200 day moving average of $338.75. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Evelyn Partners Investment Management LLP grew its holdings in shares of Alnylam Pharmaceuticals by 11.5% in the second quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 30 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares during the period. Bayforest Capital Ltd raised its position in shares of Alnylam Pharmaceuticals by 14.6% in the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 39 shares during the last quarter. MAI Capital Management raised its position in shares of Alnylam Pharmaceuticals by 9.2% in the 2nd quarter. MAI Capital Management now owns 488 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 41 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its position in shares of Alnylam Pharmaceuticals by 32.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 44 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on ALNY. Oppenheimer raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price objective on the stock in a report on Monday, August 4th. The Goldman Sachs Group upped their price objective on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $570.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 2nd. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Raymond James Financial started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price target on the stock. Twenty-four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $439.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.